JNJ Inks COVID-19 Vaccine Supply Pact With African Union

Johnson and Johnson JNJ, through its Janssen Pharmaceutical NV unit, has entered into a deal with the African Vaccine Acquisition Trust that could order an additional 180 million doses of COVID-19 shot for a combined total of 400 million doses through 2022.

  • JNJ will initially supply up to 220 million doses of the COVID-19 vaccine to the African Union's 55 member states from the third quarter of 2021.
  • "We need to immunize at least 60% of our population in order to get rid of the virus from our continent. The J&J agreement enables us to move towards achieving this target," said John Nkengasong, director of the Africa Centers for Disease Control and Prevention.
  • Last year in December, J&J said it and the GAVI vaccine alliance expected to enter into a deal that would provide up to 500 million doses of the company's vaccine to the COVAX program through 2022.
  • Johnson & Johnson has established a global manufacturing and supply network for its COVID-19 vaccine, collaborating with nine partners across four continents, including Aspen Pharmacare in South Africa.
  • Price Action: JNJ shares are trading 0.7% lower at $163.78 in the premarket on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsGeneralCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!